Aurinia Pharmaceuticals Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.
Robertson Stephen P. (Chief Legal Officer) sold 11,939 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.95 ($0.19M total) on 2026-09-10.
Robertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AUPH (Aurinia Pharmaceuticals Inc.). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent AUPH coverage spans financial news, insider activity and earnings.
In the last 30 days, AUPH insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($546K). The most active reporter was Robertson Stephen P., Chief Legal Officer, with 2 filings.
Strong profit growth may support short-term upside, but higher R&D spend and cash burn could limit longer-term rally.
Minor dilution of insider ownership; unlikely to move price materially.
Insider sale may signal negative sentiment from an executive.
Potential modest increase in share supply could exert slight downward pressure on AUPH.
Settlement removes immediate generic competition risk, supporting short‑term upside.
AlphAI scores every news story that mentions AUPH with an AI model for sentiment and relevance, and aggregates insider trades from Aurinia Pharmaceuticals Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Aurinia Pharmaceuticals reported Q2 revenue of $83.2M, up 19%, and net income of $37.4M, up 74%. LUPKYNIS sales rose 19% to $79.4M. The company reiterated 2026 guidance and initiated a new Phase 4 study. R&D spending doubled, and tax expenses increased significantly. Cash reserves grew to $443.1M, despite a $74.9M share buyback.
2 min readRobertson Stephen P. (Chief Legal Officer) sold 11,939 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $15.95 ($0.19M total) on 2026-09-10.
1 min readRobertson Stephen P. (Chief Legal Officer) sold 20,975 shares of Aurinia Pharmaceuticals Inc. (AUPH) at $16.97 ($0.36M total) on 2026-08-21.
1 min readAurinia Pharmaceuticals (AUPH) officer Stephen P. Robertson plans to sell 47,000 shares under Rule 144 to cover tax obligations from vesting performance stock units, with the sale expected to occur on or after 08/21/2026. The transaction will be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
1 min readAurinia Pharmaceuticals (AUPH) settled with Teva, delaying generic competition for voclosporin until 2036. AUPH shares rose 13.77% in 7 days, 12.51% YTD, closing at $17.27. Revenue is projected to grow 16-21% this year, with EPS potentially doubling. The stock is considered 17.8% undervalued with a fair value of $21.00, but faces risks like concentration around Lupkynis.
2 min readModerna (MRNA) and Merck (MRK) rose sharply after positive Phase 3 trial data for a skin cancer therapy. Biotech sector, up 40% YTD, saw gains. Aurinia (AUPH) settled litigation with Teva (TEVA), removing uncertainty. Ocular (OCUL) received positive analyst ratings. Precigen (PGEN) reported strong Q2 revenue and expects cash flow breakeven by year-end.
3 min readAurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.
2 min readAurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.
2 min readAurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), with Teva agreeing to not launch its generic voclosporin product until Dec. 7, 2036. Aurinia's Lupkynis is the first FDA-approved oral therapy for lupus nephritis. AUPH shares rose 2.66% premarket to $16.60, trading above its 20-day SMA of $15.31.
2 min readAurinia Pharmaceuticals (AUPH) shares fell 2% after announcing a patent settlement with Teva (TEVA) for generic voclosporin, allowing Teva to launch its version no earlier than 2036. The agreement validates Aurinia's patents and resolves litigation. Voclosporin is marketed as LUPKYNIS for lupus nephritis. Aurinia continues patent actions against other companies.
4 min read
